NCT05520086View on ClinicalTrials.gov

Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

June 11, 2024

Study Completion Date

November 11, 2024

Conditions
Chronic ConjunctivitisStevens-Johnson SyndromeLyell SyndromePemphigoid
Interventions
DRUG

Single Dose

Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.

DRUG

Double Dose

Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.

Trial Locations (8)

13600

Hospital General La Mancha Centro, Alcázar de San Juan

14012

Hospital La Arruzafa, Córdoba

28007

Hospital General Universitario Gregorio Marañon, Madrid

28040

Hospital Universitario Fundación Jiménez Diaz, Madrid

28046

Hospital Universitario La Paz, Madrid

33012

Instituto Oftalmológico Fernández - Vega, Oviedo

47003

Hospital Clínico Universitario de Valladolid, Valladolid

48903

Hospital Universitario de Cruces, Barakaldo

All Listed Sponsors
collaborator

Effice Servicios Para la Investigacion S.L.

INDUSTRY

lead

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER